Company Profile

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes.

The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

Latest Presentation

Industry Classifications

Sector:
Health

Industry:
Specialty Pharma

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical and Medicine Industry (3741)

Contact Information

Investor Relations
Crescendo Communications, LLC
Chrysler Building - 405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020
ACST@crescendo-ir.com

Company Contact
Acasti Pharma Inc.
3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5
Canada